Friday, 30 November 2012

New mechanism for cancer progression discovered

The protein called Ras plays an important role in the control of cellular growth. Researchers have focused on this protein because mutations in its gene are found in over 30% of all cancers, making it the most prevalent human oncogene.

However, researchers from Harvard and the University of North Carolina Lineberger Comprehensive Cancer Center have discovered an alternative mechanism for activating Ras; this new way does not require mutation or hormonal stimulus. In healthy cells, Ras transmits hormone signals that prompt cell growth and the development of organs and tissues, but if a mutation occurs these signals can become chronically activated, leading to tumour initiation and progression.

In an article published by Nature Structural and Molecular Biology, the UNC and Harvard teams discovered that it is possible to lock Ras into an active signalling state. They did this by modifying Ras at a specific site with a single small protein called ubiquitin, a process known as monoubiquitination, in which the action of another protein, known as the GTPase activating protein, is disrupted.

Because of the strong link between Ras and cancer, it should be an attractive target for drug therapies, but despite considerable efforts to develop treatments that target the protein, it is now considered to be 'undruggable'. The researchers next step then will be to gain a better understanding of its role in cancer progression, firstly using cells then moving on to animals and eventually cancer patients.

Jack

Friday, 23 November 2012

Mutant cells increase cancer risk

According to new research from USC, certain mutated cells in cancer patients keep trying to replicate their DNA with disastrous results, even when the materials required to do so have been taken away by medication.

The team that carried out the study used a common chemotherapy drug to put stress on fission yeast cells while they were undergoing DNA replication, it works by starving the cells of nucleotides which are used to build DNA strands.

New imaging techniques have shown that while chemotherapy shuts down the DNA replication of most cancer cells, so-called "checkpoint mutants" continue to create damaged DNA strands that can result in cancer-like abnormalities. Older methods suggested these mutants stopped replicating and the replication machinery simply fell apart, but the new technique shows the processes continue and actively contribute to the damage.

It has also been shown in previous studies that normal cells recognise the loss of nucleotides and stop trying to replicate their DNA. However the researchers found that the checkpoint mutants ignore the signal to do this. They continue to replicate their DNA, unwinding the strands, until the DNA strands reach a "collapse point" where they break, this is arguably the worst kind of damage that can be done to a cell.

The next step after this study will be to find out what happens to the small number of cells that survive this treatment.

Jack

Friday, 16 November 2012

Rare mutation linked to Alzheimer's

Two separate studies published online this week, by the New England Journal of Medicine, both point to a link between Alzheimer's disease and a rare gene mutation. The mutation in question is known to affect the immune system's response to inflammation. This discovery supports an emerging theory about the role played by the immune system in the development of Alzheimer's disease.

One of the teams was led by John Hardy of University College London, and the other led by the Iceland-based global company deCode Genetics.

Both teams concluded that a rare mutation in a gene called TREM2, which helps to trigger immune system responses, increases the risk of developing Alzheimer's disease. One of the studies suggests it raises the risk by three times, the other says four. The lead author of the UCL study, Rita Guerreiro, commented: "While the genetic mutation we found is extremely rare, its effect on the immune system is a strong indicator that this system may be a key player in the disease."

In the UCL-led study, researchers from 44 institutions from around the world analysed data from a total of 25,000 people. They used new sequencing techniques to home in on the TREM2 gene, and then used more sequencing to identify a set of rare mutations. They then discovered that the mutations were more prevalent in the 1,092 Alzheimer's patients than in the 1,107 healthy controls. The co-author, Minerva Carrasquillo, said "In our series, it was present in 1.9 percent of the Alzheimer's patients and in only 0.37 percent of the controls."

Also the CEO and co-founder of deCode Genetics said: "The discovery of variant TREM2 is important because it confers high risk for Alzheimer's and because the gene's normal biological function has been shown to reduce immune response that may contribute to the disease." He went on to say that these factors make TREM2 an attractive target for drug development.

Jack

Friday, 9 November 2012

Gene-expression switches play major role in cancer

Scientists from the Karolinska Institutet in Sweden and the University of Helsinki in Finland have shown that the 'switches' which regulate gene expression play a major role in the development of cancer. In a study that was published in the journal Science they investigated a variant of nucleotide that is associated with an increased risk of colorectal and prostate cancer. They also found that removing the DNA region where the nucleotide is found caused dramatic resistance to tumour formation.

Various other studies have discovered genomic regions similar to this that are associated with over 200 diseases, including heart disease, diabetes and different types of cancer. This has attracted much attention from both scientific and popular press but the mechanisms by which these genomic regions act are not fully understood.

In the study the scientists removed the gene region containing the nucleotide variant from the mouse genome, they found that as a result the mice were healthy but also showed a small decrease in the expression of a nearby cancer gene, called MYC. But although the decrease was only small they showed dramatic resistance to tumour formation when tested. This shows then that the gene region that was removed acts as an important pro-cancer gene switch, and removing it causes tumours to develop much more rarely.

According to the scientists, the results show that although the gene variants, which make individual humans different from each other, generally have a small impact on diseases development, the gene switches in which they reside can play a major role. Therefore this technique seems to have potential for cancer prevention in future.

Jack

Friday, 2 November 2012

First gene therapy backed by Europe

For the first time a treatment that corrects errors in a person's genetic code has been approved for commercial use in Europe.

The field of gene therapy has a simple aim, to correct the genetic code of people with genetic conditions, but it has been plagued with problems over the years. Some patients have developed leukaemia and in one US trial a teenage patient died.

Glybera, which is a gene therapy for a rare disease that leaves people unable to properly digest fats, has been given marketing authorisation by the European Commission. This means that it can be sold throughout the EU and the manufacturers, UniQure, say it will become available next year. Lipoprotein lipase deficiency, the disease in question, means that fat build-ups develop in the blood causing abdominal pain and life-threatening pancreatitis. At the moment the only way to manage the condition is by having a very low-fat diet. The new treatment works, as does every other gene therapy treatment, by using a virus to infect muscle cells with a working copy of the gene.

The CEO of UniQure, Jorn Aldag, said: "The final approval of Glybera from the European Commission marks a major step forward in making gene therapies available not only for lipoprotein lipase deficiency, but also for a large number of rare diseases with a very high unmet medical need." Also the company said it planned to apply for regulatory approval in the US and Canada, allowing the treatment to be given to more sufferers of the disease.

Hopefully this will now spur on more research into gene therapy and lead to new treatments that can treat a variety of genetic diseases, without the troubling side effects that have been seen in the past.

Jack